首页> 外文期刊>Breast Cancer Research and Treatment >The p160 ER co-regulators predict outcome in ER negative breast cancer
【24h】

The p160 ER co-regulators predict outcome in ER negative breast cancer

机译:p160 ER协同调节剂可预测ER阴性乳腺癌的预后

获取原文
获取原文并翻译 | 示例
           

摘要

The SRC family of ER co-regulators are frequently overexpressed in breast cancer. Overexpression of AIB1 appears to be linked to hormone resistance in HER2 positive breast cancer. However, the role of these co-regulators in ER negative disease is poorly understood. SRC1, SRC2 and AIB1 expression was determined by immunohistochemical analysis of tissue microarrays constructed from tumours within the Edinburgh Breast Conservation Series (BCS). The BCS represents a fully documented consecutive cohort of 1,812 patients treated by breast conservation surgery in a single institution. Our results demonstrate tumours that overexpress both HER2 and AIB1 were associated with markedly reduced relapse free, distant relapse free and overall survival compared to HER2 and AIB1 only overexpressing tumours irrespective of ER status. In ER negative disease both SRC1 and AIB1 were linked to early relapse and death. The SRC family of ER co-regulators is involved in early relapse and resistance in both ER negative and ER positive breast cancer challenging the conventional concept that this effect is mediated solely via the ER.
机译:ER辅助调节剂的SRC系列在乳腺癌中经常过表达。在HER2阳性乳腺癌中,AIB1的过度表达似乎与激素抵抗有关。然而,人们对这些共调节剂在ER阴性疾病中的作用了解甚少。 SRC1,SRC2和AIB1的表达是通过对组织微阵列的免疫组织化学分析确定的,该组织由爱丁堡乳房保护系列(BCS)内的肿瘤构成。 BCS代表了在单个机构中连续记录的1,812例通过保乳手术治疗的患者。我们的结果表明,与仅过表达HER2和AIB1的肿瘤(无论ER状态如何)相比,过表达HER2和AIB1的肿瘤与无复发,远处无复发和总体生存率显着降低有关。在ER阴性疾病中,SRC1和AIB1均与早期复发和死亡有关。 SRC ER辅助调节剂家族参与ER阴性和ER阳性乳腺癌的早期复发和耐药,这挑战了仅通过ER介导这种作用的传统观念。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号